Imiquimod Tested as Nonsurgical Option

WASHINGTON - Imiquimod 5 percent cream (Aldara) continues to demonstrate promise as an effective and well tolerated topical therapy for the treatment of primary, superficial basal cell carcinoma, according to results from foreign and domestic Phase II dose-response studies presented at the annual meeting of the American Academy of Dermatology.